74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Bridgebio Pharma Inc
Open
SectorHealthcare
75.72 -1.83
Overview
Share price change
24h
Min
74.79
Max
76.91
Income | -7.5M -190M |
|---|---|
Sales | 33M 154M |
Profit margin | -123.403 |
Employees | 834 |
EBITDA | -6.9M -180M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +33.63% upside |
Next Earnings | 28 Apr 2026 |
|---|
Market Cap | 2.1B 15B |
|---|---|
Previous open | 77.55 |
Previous close | 75.72 |
News Sentiment
By Acuity
50%
50%
159 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Bridgebio Pharma Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bridgebio Pharma Inc Forecast
Price Target
By TipRanks
33.63% upside
12 Months Forecast
Average 102.56 USD 33.63%
High 157 USD
Low 69 USD
Based on 18 Wall Street analysts offering 12 month price targets forBridgebio Pharma Inc - Dist in the last 3 months.
Sentiment
By Acuity
159 / 348 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bridgebio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Live chat